Faron’s Post

Our CEO Dr. Juho Jalkanen MD, PhD is attending the Proactive One2One Biotech Investor Forum this evening in London, an event bringing together biotech companies and investors to explore investment opportunities and foster valuable connections.   Please reach out if you would like to hear more about #bexmarilimab, our wholly owned #immunotherapy candidate, for the treatment of myelodysplastic syndrome (MDS) patients that have failed a hypomethylating agent (HMA) which has recently been granted Fast Track Designation (FTD) by the FDA.   To register for the event, visit: https://lnkd.in/etvMswBw   #Forum #Investors #Faron #bexmarilimab #Biotech #DrugDevelopment

Faron will be hosting a hybrid Capital Markets Day on Tuesday, 22 October 2024 at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST). Our CEO Dr. Juho Jalkanen MD, PhD, alongside other senior members of the management team including our CMO Dr. Petri Bono and CSO Dr. Maija Hollmén will provide an overview and update on the clinical development plan for bexmarilimab in solid tumours. Dr. Mika Kontro, Principal Investigator of the BEXMAB trial and Mr. Ralph Hughes will present updated survival data from the ongoing BEXMAB Phase I/II trial and results of recently conducted market research in MDS, discussing bexmarilimab’s further potential as a first-in-class immune-oncological treatment. Register to watch the webcast here: https://lnkd.in/diRv8yWW If you’d like to attend the event in person, please contact: investor.relations@faron.com before 2:00 pm (EEST) on 18 October 2024. Read the full press release here: https://lnkd.in/d8_DS7dw #Faron #biotech #drugdevelopment #oncology

We are delighted to announce that we have been shortlisted for the ‘Best Oncology R&D Advance’ Award at the Citeline Scrip Awards.     This is testament to the significant progress we’ve made this year in advancing #bexmarilimab, our wholly owned #immunotherapy candidate, through clinical development, and recognition of our differentiated approach to immuno-oncology research, and commitment to bringing new treatment options to patients in need.      Congratulations to all finalists!     #Awards #Faron #biotech #drugDevelopment #oncology 

Our CEO Dr Juho Jalkanen MD, PhD and CMO Dr Petri Bono are heading to Barcelona later this week for the ESMO - European Society for Medical Oncology Congress 2024.   As one of the most influential global #oncology conferences, the ESMO Congress is an opportunity for us to catch up with clinicians, researchers, patient advocates and the broader #healthcare industry, about the latest advancements in research and patient care.   If you’ll be there and would like to connect, do let us know.   For more information, visit: https://lnkd.in/eSBEG7fw   #Conference #Faron #bexmarilimab #Biotech #DrugDevelopment  

We are delighted to announce that #bexmarilimab, our wholly owned #immunotherapy candidate, has been granted Fast Track Designation (FTD) by the FDA for the treatment of relapsed or refractory myelodysplastic syndrome (r/r MDS) in combination with azacitidine.   Given the previously reported promising results in both Phase 1 and 2 of our BEXMAB trial when treating r/r MDS patients using a combination of bexmarilimab and azacitidine to overcome primary or developed resistance to azacitidine, bexmarilimab has been granted Fast Track Designation subsequent to the accelerated development plan proposed by the FDA in July.   This FTD further strengthens the bexmarilimab program by offering clinical development and commercialization benefits.   Read the full press release here https://lnkd.in/enWYY3tk   #Faron #Biotech #drugDevelopment 

We are pleased to announce Faron has joined a research consortium that has received a United States Department of Defense (DoD) Grant to investigate the use of Traumakine®, our intravenous interferon beta-1a therapy, in preventing ischemia-reperfusion injury in battlefield victims when using a lifesaving torniquet. To read more, visit: https://lnkd.in/eKub9r7r   #Faron #Biotech #drugdevelopment

We are thrilled to announce the appointment of Yrjö E K Wichmann, Faron’s current interim CFO, as our permanent CFO.   Yrjö previously served as our CFO between 2014-2019, and his in-depth knowledge of the Company alongside his critical expertise as an accomplished biotech and financial executive with over 20 years of experience in financing and investment banking will continue to play a pivotal role in strengthening the Company and advancing #bexmarilimab, our proprietary immunotherapy asset.   Press release here: https://lnkd.in/eYUSAZTy   #Appointment #Faron #Biotech #drugdevelopment #oncology

We are delighted to welcome Dr. Petri Bono to Faron as our new Chief Medical Officer. Dr. Bono will succeed Dr. Birge Berns, MD, MRCP, FFPM, who will continue her role as part of Faron’s medical leadership team involved in developing #bexmarilimab.   Dr. Bono’s translational and clinical studies in targeted therapies and applied immunology will be invaluable in supporting Faron's immuno-oncology program and progressing our wholly-owned immunotherapy asset, #bexmarilimab, to a broader patient population.   To read the full press release, please visit: https://lnkd.in/eJ3MX98r   #Appointment #Faron #Biotech #drugdevelopment #oncology

We’re #hiring. Join our team to make a difference! Interested and confident you could be the person we are looking for? Please send us your cover letter and CV in English by 1st September. https://lnkd.in/dUT_8PcF

We are delighted to be featured in LA Weekly. The article outlines Faron’s journey so far in developing #bexmarilimab, Faron’s humanized monoclonal antibody to overcome treatment resistance in both hematological malignancies and solid tumors, highlighting our differentiated mode of action and accelerated approval plans on the back of recent positive FDA feedback.   To read the article, visit: https://lnkd.in/dwkv3Y6A   #Faron #biotech #drugDevelopment